Time to menarche and final height after histrelin implant treatment for central precocious puberty

Journal of Pediatrics

Volumn 163, Issue 2, 2013, Pages 532-536

  Gillis, David ^a   Karavani, Gilad ^b   Hirsch, Harry J ^c   Strich, David ^d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d CLALIT HEALTH SERVICES   (Israel)

Author keywords

BMI; Body mass index; Central precocious puberty; CPP; Follicle stimulating hormone; FSH; GnRHa; Gonadotropin releasing hormone agonist(s); LH; Luteinizing hormone; Not significant; NS; PAH; Predicted adult height; TD; Triptorelin depot

Indexed keywords

GONADORELIN AGONIST; HISTRELIN; TRIPTORELIN;

ARTICLE; BODY HEIGHT; BODY MASS; CHILD; CLINICAL ARTICLE; FEMALE; GROWTH RATE; HUMAN; IMPLANTATION; INTERVIEW; MEDICAL RECORD REVIEW; MENARCHE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION;

BMI; BODY MASS INDEX; CENTRAL PRECOCIOUS PUBERTY; CPP; FOLLICLE STIMULATING HORMONE; FSH; GNRHA; GONADOTROPIN RELEASING HORMONE AGONIST(S); LH; LUTEINIZING HORMONE; NOT SIGNIFICANT; NS; PAH; PREDICTED ADULT HEIGHT; TD; TRIPTORELIN DEPOT;

AGE FACTORS; BODY HEIGHT; BODY MASS INDEX; CHILD; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MENARCHE; PUBERTY, PRECOCIOUS; TRIPTORELIN PAMOATE;

EID: 84880627462     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2013.01.021     Document Type: Article

References (24)

1. J.C. Carel, E.A. Eugster, A. Rogol, L. Ghizzoni, and M.R. Palmert Consensus statement on the use of gonadotropin-releasing hormone analogs in children Pediatrics 123 2009 e752 e762
2. H.J. Hirsch, D. Gillis, D. Strich, B. Chertin, A. Farkas, and T. Lindenberg The histrelin implant: a novel treatment for central precocious puberty Pediatrics 116 2005 e798 e802
3. E.A. Eugster, W. Clarke, G.B. Kletter, P.A. Lee, E.K. Neely, and E.O. Reiter Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial J Clin Endocrinol Metab 92 2007 1697 1704
4. H.J. Hirsch, N. Lahlou, D. Gillis, D. Strich, B. Rosenberg-Hagen, and B. Chertin Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant J Clin Endocrinol Metab 95 2010 2841 2844
5. Silverman LA, Kletter GB, Neely EK, Potts S, Gould E, Terleckyj, et al. Recovery of normal hypothalamic-pituitary-gonadal function after treatment with subcutaneous histrelin implant for central precocious puberty. Abstract, presented at Endocrine Society Meeting. June 23-26, 2012; Houston, TX. Available at: http://www.abstracts2view.com/endo/view.php?nu=ENDO12L-SUN-628. Accessed February 13, 2013.
6. M. Lampit, A. Golander, H. Guttmann, and Z. Hochberg Estrogen mini-dose replacement during GnRH agonist therapy in central precocious puberty: a pilot study J clin Endocrinol Metab 87 2002 687 690
7. Strich D, Kvatinsky N, Hirsch HJ, Gillis D. Triptorelin depot stimulation test for central precocious puberty. J Pediatr Endocrinol Metab 2012, in press.
8. W.W. Greulich, and S.I. Pyle Radiographic atlas of skeletal development of the hand and wrist 2nd ed. 1959 Stanford University Press Stanford
9. E.M. Post, and R.A. Richman A condensed table for predicting adult stature J Pediatr 98 1981 440 442
10. R. Kauli, A. Galatzer, L. Kornreich, L. Lazar, A. Pertzelan, and Z. Laron Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with reevaluation of predictions by the Bayley-Pinneau method Horm Res 47 1997 54 61
11. E.K. Neely, P.A. Lee, C.A. Bloch, L. Larsen, D. Yang, and C. Mattia-Goldberg Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery Int J Pediatr Endocrinol 2010 2010 398639
12. A. Cassio, M.O. Bal, L.F. Orsini, A. Balsamo, S. Sansavini, and M. Gennari Reproductive outcome in patients treated and not treated for idiopathic early puberty: long-term results of a randomized trial in adults J Pediatr 149 2006 532 536
13. T. Arrigo, F. De Luca, F. Antoniazzi, F. Galluzzi, L. Iughetti, and A.M. Pasquino Menstrual cycle pattern during the first gynaecological years in girls with precocious puberty following gonadotropin-releasing hormone analogue treatment Eur J Pediatr 166 2007 73 74
14. A.M. Pasquino, I. Pucarelli, F. Accardo, V. Demiraj, M. Segni, and R. Di Nardo Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function J Clin Endocrinol Metab 93 2008 190 195
15. P.C. Sizonenko, and M.L. Aubert Neuroendocrine changes characteristic of sexual maturation J Neural Transm 21 Suppl 1986 159 181
16. L. Lazar, A. Padoa, and M. Phillip Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity J Clin Endocrinol Metab 92 2007 3483 3489
17. W.F. Paterson, E. McNeill, D. Young, and M.D. Donaldson Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty Clin Endocrinol (Oxf) 61 2004 626 634
18. I.M. van der Sluis, A.M. Boot, E.P. Krenning, S.L. Drop, and S.M. de Muinck Keizer-Schrama Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy J Clin Endocrinol Metab 87 2002 506 512
19. C. Traggiai, P.P. Perucchin, K. Zerbini, R. Gastaldi, P. De Biasio, and R. Lorini Outcome after depot gonadotropin-releasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height Eur J Endocrinol 153 2005 463 464
20. P.P. Feuillan, J.V. Jones, K. Barnes, K. Oerter-Klein, and G.B. Cutler Jr. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty J Clin Endocrinol Metab 84 1999 44 49
21. S. Heger, C.J. Partsch, and W.G. Sippell Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function J Clin Endocrinol Metab 84 1999 4583 4590
22. F. Antoniazzi, G. Zamboni, F. Bertoldo, S. Lauriola, F. Mengarda, and A. Pietrobelli Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation J Clin Endocrinol Metab 88 2003 1096 1101
23. T. Arrigo, F. De Luca, F. Antoniazzi, F. Galluzzi, M. Segni, and M. Rosano Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty Eur J Endocrinol 150 2004 533 537
24. A. Messaaoui, G. Massa, S. Tenoutasse, and C. Heinrichs Treatment of central precocious puberty with gonadotropin-releasing hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height, and weight evolution during and after treatment Rev Med Brux 26 2005 27 32